LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
Last week saw three key settlements, including a lab accused of paying kickbacks for test referrals and billing for unnecessary drug tests.
The U.S. Department of Justice recently announced inflationary increases to civil monetary penalties under the False Claims Act.
Current provider pay rates are “adequate,” says influential committee in its recent report to Congress.
U.S. Department of Health and Human Services secretary takes action to ensure continued access to COVID-19 EUA products.
Last week saw two key lab-related cases, with the biggest involving a fraud scheme relating to cancer genetic testing.
HHS orders arbitrators to go back to resolving payment disputes between providers and payors under the No Surprises Act.
This week’s cases involved false billing allegations related to urine drug testing, as well as diagnostic imaging false claims and fraud.
Recently released AACC document covers newly updated screening guidelines as well as information on surveillance and diagnosis.
Enzo recently announced that it is selling its lab division to LabCorp for $146 million in cash.
A recently released report estimates that the US market will grow at a CAGR of 4.2 percent over the next seven years.